Skip to main content
    O

    Oruka Therapeutics, Inc. (ORKA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $96.32
    -2.92 (-2.94%)

    Market Cap: $6.73B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Oruka Therapeutics, Inc. (ORKA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Oruka Therapeutics (ORKA) has a market cap of $6.73B. Its share count is up 62.46% from a year earlier.

    Total Valuation

    Market Cap$6.73B
    Latest price (Nov 17, 2026)$96.32

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 13.87% in the quarter ended Sep 30, 2026 and grew 118.37% a year over 2 years.

    Shares Outstanding71.59M
    Shares Change (YoY)+62.46%
    Shares Change (QoQ)+13.87%
    Share Count Growth (2Y CAGR)+118.37%

    Price Statistics

    The stock is up 255.69% over 52 weeks and trades 7.20% above its 50-day average.

    Beta (1Y)1.48
    52-Week Change+255.69%
    1-Month Change+29.32%
    3-Month Change-12.19%
    6-Month Change+67.51%
    5-Year Change+194.50%
    10-Year Change-79.61%
    Total Return (1Y)+255.69%
    Total Return (3Y CAGR)+93.92%
    Total Return (5Y CAGR)+42.00%
    Return vs SPY (1Y)+239.33%
    Max Drawdown (1Y)-36.39%
    Max Drawdown (3Y)-77.76%
    Sharpe Ratio (1Y)1.87
    Correlation with SPY (1Y)0.30
    50-Day Average$89.85
    200-Day Average$73.29
    52-Week Range$25.23 to $115.52
    RSI (14 Days)50.9
    Average Volume (20 Days)1.01M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 29.62x current liabilities.

    Current Ratio29.62x
    Quick Ratio29.62x

    Returns and Efficiency

    Return on equity is -12.74% and return on assets is -12.39% over the last 12 months.

    Return on Equity (ROE)-12.74%
    Return on Assets (ROA)-12.39%
    ROIC (5Y Average)-18.92%

    Scores

    ORKA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit-$163.00K
    Operating Income-$183.11M
    Pretax Income-$152.57M
    Net Income-$152.57M
    Reported EPS (TTM)-$2.11

    Trailing 12 months through Sep 30, 2026.

    Balance Sheet

    Shareholder equity funds 97.56% of the $1.23B in total assets.

    Cash and Equivalents$191.52M
    Working Capital$909.71M
    Shareholder Equity$1.20B
    Book Value Per Share$16.72
    Total Assets$1.23B
    Total Liabilities$33.88M

    Balance sheet as of Sep 30, 2026.

    Cash Flow

    After $219.00K of capital spending, operating cash flow left -$123.86M of free cash flow.

    Operating Cash Flow-$123.64M
    Capital Expenditures$219.00K
    Free Cash Flow-$123.86M
    FCF Per Share-$1.83
    Depreciation and Amortization$163.00K

    Trailing 12 months through Sep 30, 2026.

    Growth

    Book Value Per Share Growth (2Y CAGR)+83.76%
    Tangible Book Per Share Growth (2Y CAGR)+83.76%

    Stock Splits

    The last split was a 1-for-12 reverse split on Sep 3, 2024.

    Last Split DateSep 3, 2024
    Split TypeReverse split
    Split Ratio1:12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ORKA

    What is ORKA's market cap?

    Oruka Therapeutics has a market cap of $6.73B.

    How many shares of ORKA are outstanding?

    Oruka Therapeutics has 71.59M shares outstanding. The count is up 62.46% from a year earlier.

    Does ORKA pay a dividend?

    No. Oruka Therapeutics does not pay a dividend.